Published in Nat Rev Cancer on January 01, 2010
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol (2011) 4.34
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer (2010) 3.33
Epigenetic modifications as therapeutic targets. Nat Biotechnol (2010) 3.16
Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood (2011) 2.96
The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood (2010) 2.33
Comprehensive microRNA expression profiling of the hematopoietic hierarchy. Proc Natl Acad Sci U S A (2010) 1.67
Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia (2011) 1.67
Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell (2012) 1.61
miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nat Commun (2012) 1.49
Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proc Natl Acad Sci U S A (2010) 1.43
Diagnostic usefulness of genomic breakpoint analysis of various gene rearrangements in acute leukemias: a perspective of long distance- or long distance inverse-PCR-based approaches. Ann Lab Med (2012) 1.39
C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood (2010) 1.28
MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. Blood Cells Mol Dis (2010) 1.26
Myeloid malignancies: mutations, models and management. BMC Cancer (2012) 1.24
5-hydroxymethylcytosine and its potential roles in development and cancer. Epigenetics Chromatin (2013) 1.20
TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci U S A (2013) 1.19
MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia. Proc Natl Acad Sci U S A (2012) 1.09
NKX3.1 is a direct TAL1 target gene that mediates proliferation of TAL1-expressing human T cell acute lymphoblastic leukemia. J Exp Med (2010) 1.06
Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1. Cell Rep (2015) 1.05
miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. Proc Natl Acad Sci U S A (2013) 1.01
Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2. Genes Cancer (2011) 0.99
Young intragenic miRNAs are less coexpressed with host genes than old ones: implications of miRNA-host gene coevolution. Nucleic Acids Res (2012) 0.98
MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia. Leukemia (2013) 0.96
FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N(6)-Methyladenosine RNA Demethylase. Cancer Cell (2016) 0.96
Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD. Int J Clin Exp Pathol (2014) 0.96
Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer. Mol Cancer Ther (2010) 0.93
Epigenetic changes: a common theme in acute myelogenous leukemogenesis. J Hematol Oncol (2013) 0.92
Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Curr Pharm Des (2013) 0.91
RUNX1: A microRNA hub in normal and malignant hematopoiesis. Int J Mol Sci (2013) 0.91
HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia. Oncotarget (2013) 0.89
Overexpression and knockout of miR-126 both promote leukemogenesis. Blood (2015) 0.88
HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia. J Clin Invest (2014) 0.88
The pathological role and prognostic impact of miR-181 in acute myeloid leukemia. Cancer Genet (2015) 0.87
Dissecting the chromatin interactome of microRNA genes. Nucleic Acids Res (2013) 0.83
Targeting deregulated epigenetic control in cancer. J Cell Physiol (2013) 0.82
Overexpression of miR-210 is Associated with Poor Prognosis of Acute Myeloid Leukemia. Med Sci Monit (2015) 0.82
Argonaute 2 sustains the gene expression program driving human monocytic differentiation of acute myeloid leukemia cells. Cell Death Dis (2013) 0.82
Improved therapeutic effect against leukemia by a combination of the histone methyltransferase inhibitor chaetocin and the histone deacetylase inhibitor trichostatin A. J Korean Med Sci (2013) 0.81
Identification of nuclear-enriched miRNAs during mouse granulopoiesis. J Hematol Oncol (2014) 0.81
Myeloid leukemia factor is a conserved regulator of RUNX transcription factor activity involved in hematopoiesis. Proc Natl Acad Sci U S A (2012) 0.81
Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells. BMC Genomics (2015) 0.80
Epigenetic landscape of acute myelogenous leukemia--moving toward personalized medicine. J Cell Biochem (2014) 0.80
GPX3 hypermethylation serves as an independent prognostic biomarker in non-M3 acute myeloid leukemia. Am J Cancer Res (2015) 0.80
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs (2014) 0.80
miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia. Mol Cancer (2015) 0.79
Reduced expression of the WW domain-containing oxidoreductase in human hematopoietic malignancies. Oncol Lett (2016) 0.79
The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia. Blood Cancer J (2015) 0.78
Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis. Leukemia (2016) 0.77
Retracted GPX3 hypermethylation serves as an independent prognostic biomarker in non-M3 acute myeloid leukemia. Am J Cancer Res (2015) 0.77
Differential requirement for wild-type Flt3 in leukemia initiation among mouse models of human leukemia. Exp Hematol (2013) 0.77
Reduced miR-215 expression predicts poor prognosis in patients with acute myeloid leukemia. Jpn J Clin Oncol (2016) 0.77
Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies. J Cell Mol Med (2017) 0.77
Inactivation of KLF4 promotes T cell acute lymphoblastic leukemia and activates the MAP2K7 pathway. Leukemia (2016) 0.76
Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia. Cancer Lett (2016) 0.76
Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles. Cancer Res (2016) 0.76
Identification of post-transcriptional regulatory networks during myeloblast-to-monocyte differentiation transition. RNA Biol (2015) 0.75
Southwestern Oncology Group pretreatment risk criteria as predictive or prognostic factors in acute myeloid leukemia. Mol Clin Oncol (2017) 0.75
Increased expression of miR-24 is associated with acute myeloid leukemia with t(8;21). Int J Clin Exp Pathol (2014) 0.75
miR-150:targeting MLL leukemia. Oncotarget (2012) 0.75
Pathogenesis of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse. Oncotarget (2017) 0.75
Transient resistance to DNA damaging agents is associated with expression of microRNAs-135b and -196b in human leukemia cell lines. Int J Biochem Mol Biol (2016) 0.75
New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins. Front Biol (Beijing) (2016) 0.75
MicroRNAs in the pathogenesis of myelodysplastic syndromes and myeloid leukaemia. Curr Opin Hematol (2014) 0.75
Novel tumor suppressor function of KLF4 in pediatric T-cell acute lymphoblastic leukemia. Exp Hematol (2017) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 46.47
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet (2004) 37.83
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
c-Myc-regulated microRNAs modulate E2F1 expression. Nature (2005) 31.81
RAS is regulated by the let-7 microRNA family. Cell (2005) 30.24
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
MicroRNA-directed cleavage of HOXB8 mRNA. Science (2004) 18.33
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Requirement of bic/microRNA-155 for normal immune function. Science (2007) 16.24
Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (1973) 15.28
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A (2004) 14.59
Selective blockade of microRNA processing by Lin28. Science (2008) 14.39
The history of cancer epigenetics. Nat Rev Cancer (2004) 14.38
Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science (2007) 12.42
Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell (2008) 12.29
Regulation of the germinal center response by microRNA-155. Science (2007) 12.25
Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A (1982) 11.15
Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A (2006) 10.65
Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A (1982) 10.50
A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res (2005) 10.46
Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol (2008) 10.42
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol (2002) 9.83
AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell (1996) 9.74
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet (1999) 9.53
Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell (1991) 9.40
The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell (1991) 8.98
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer (2006) 8.57
MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer (2007) 8.17
MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell (2002) 8.17
Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol (2007) 8.14
Acute lymphoblastic leukemia. N Engl J Med (2004) 7.83
Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell (1984) 6.78
ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell (2002) 6.72
microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity (2007) 6.72
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev (2007) 6.71
Oncogenic transcription factors in the human acute leukemias. Science (1997) 6.45
Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov (2006) 6.39
Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A (1996) 6.29
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood (1988) 6.09
Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med (2008) 5.97
hDOT1L links histone methylation to leukemogenesis. Cell (2005) 5.83
Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (1998) 5.63
Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell (2008) 5.53
Acute promyelocytic leukemia: from highly fatal to highly curable. Blood (2008) 5.35
Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 5.30
The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature (1990) 5.24
H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 5.23
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood (2008) 5.23
An E2F/miR-20a autoregulatory feedback loop. J Biol Chem (2006) 5.20
FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist (2007) 4.95
MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med (2008) 4.91
The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet (1996) 4.59
Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem (2006) 4.57
Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature (1984) 4.30
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A (2008) 4.26
Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell (2008) 4.20
Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol (2007) 4.17
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res (2006) 4.15
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol (2008) 4.09
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood (2003) 4.07
CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci U S A (2007) 4.06
MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation. Nat Cell Biol (2007) 4.02
MicroRNAs control de novo DNA methylation through regulation of transcriptional repressors in mouse embryonic stem cells. Nat Struct Mol Biol (2008) 3.98
MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci U S A (2009) 3.97
Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood (2002) 3.89
MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A (2006) 3.80
Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol (2006) 3.71
The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell (2005) 3.70
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood (2007) 3.60
ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A (1998) 3.59
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med (1991) 3.52
MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood (2008) 3.50
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol (2006) 3.50
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood (2006) 3.48
The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet (2006) 3.39
Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A (2005) 3.37
Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med (1993) 3.37
Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science (1990) 3.34
Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. J Clin Invest (2006) 3.27
Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci U S A (1991) 3.25
Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell (2007) 3.16
Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol (1998) 3.13
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A (2008) 3.13
HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood (2008) 3.12
ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol (1998) 3.06
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol (2008) 3.02
Chromosome translocations: dangerous liaisons revisited. Nat Rev Cancer (2001) 3.01
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A (2007) 3.00
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood (2003) 4.15
Over 20% of human transcripts might form sense-antisense pairs. Nucleic Acids Res (2004) 3.45
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A (2008) 3.13
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia. N Engl J Med (2015) 3.00
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A (2007) 3.00
Identifying novel transcripts and novel genes in the human genome by using novel SAGE tags. Proc Natl Acad Sci U S A (2002) 2.87
A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med (2006) 2.36
Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood (2009) 2.11
Genome-wide analysis of coordinate expression and evolution of human cis-encoded sense-antisense transcripts. Trends Genet (2005) 2.04
Chromatin structural elements and chromosomal translocations in leukemia. DNA Repair (Amst) (2006) 2.01
The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med (2002) 1.75
Oligo(dT) primer generates a high frequency of truncated cDNAs through internal poly(A) priming during reverse transcription. Proc Natl Acad Sci U S A (2002) 1.71
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma (2012) 1.57
Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood (2011) 1.55
ISCN (2005) is not acceptable for describing clonal evolution in cancer. Genes Chromosomes Cancer (2007) 1.44
Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2006) 1.44
Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proc Natl Acad Sci U S A (2010) 1.43
Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol (2011) 1.39
Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias. Cancer Res (2009) 1.35
Human antisense genes have unusually short introns: evidence for selection for rapid transcription. Trends Genet (2005) 1.35
Molecular portraits of B cell lineage commitment. Proc Natl Acad Sci U S A (2002) 1.32
PBX3 is an important cofactor of HOXA9 in leukemogenesis. Blood (2012) 1.30
The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin. Proc Natl Acad Sci U S A (2004) 1.22
TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci U S A (2013) 1.19
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res (2013) 1.19
Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia. Proc Natl Acad Sci U S A (2002) 1.16
Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol (2013) 1.15
Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. J Exp Med (2005) 1.12
Correct identification of genes from serial analysis of gene expression tag sequences. Genomics (2002) 1.09
MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia. Proc Natl Acad Sci U S A (2012) 1.09
Retracted Silencing of B cell receptor signals in human naive B cells. J Exp Med (2002) 1.09
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol (2013) 1.05
T lymphoid differentiation in human bone marrow. Proc Natl Acad Sci U S A (2003) 1.03
miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. Proc Natl Acad Sci U S A (2013) 1.01
A novel gene, MDS2, is fused to ETV6/TEL in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome. Genes Chromosomes Cancer (2002) 1.01
Gene expression profiles in acute myeloid leukemia with common translocations using SAGE. Proc Natl Acad Sci U S A (2006) 1.01
Characterization of genomic breakpoints in MLL and CBP in leukemia patients with t(11;16). Genes Chromosomes Cancer (2004) 1.00
Local gene density predicts the spatial position of genetic loci in the interphase nucleus. Exp Cell Res (2005) 1.00
The transcriptome of human CD34+ hematopoietic stem-progenitor cells. Proc Natl Acad Sci U S A (2009) 0.98
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2008) 0.98
Unique balanced chromosome abnormalities in treatment-related myelodysplastic syndromes and acute myeloid leukemia: report from an international workshop. Genes Chromosomes Cancer (2002) 0.96
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res (2008) 0.95
Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells. Proc Natl Acad Sci U S A (2005) 0.95
Critical role of miR-9 in myelopoiesis and EVI1-induced leukemogenesis. Proc Natl Acad Sci U S A (2013) 0.94
Knockdown of Pu.1 by small interfering RNA in CD34+ embryoid body cells derived from mouse ES cells turns cell fate determination to pro-B cells. Proc Natl Acad Sci U S A (2005) 0.94
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 0.92
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs (2008) 0.91
The small introns of antisense genes are better explained by selection for rapid transcription than by "genomic design". Genetics (2005) 0.90
A t(11;15) fuses MLL to two different genes, AF15q14 and a novel gene MPFYVE on chromosome 15. Oncogene (2003) 0.90
Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome. Cancer Genet (2011) 0.89
Screening and quantification of multiple chromosome translocations in human leukemia. Clin Chem (2003) 0.88
The dawn of the molecular era of the myelodysplastic syndromes. N Engl J Med (2011) 0.87
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Am J Hematol (2012) 0.87
New fusion transcripts identified in normal karyotype acute myeloid leukemia. PLoS One (2012) 0.87
Duplexes of 21-nucleotide RNAs mediate RNA interference in differentiated mouse ES cells. Biol Cell (2003) 0.86
PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22). Genes Chromosomes Cancer (2004) 0.85
Methylation-independent silencing of the tumor suppressor INK4b (p15) by CBFbeta-SMMHC in acute myelogenous leukemia with inv(16). Cancer Res (2007) 0.84
Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leuk Lymphoma (2007) 0.84
Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. Leuk Lymphoma (2011) 0.84
Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies. Curr Hematol Malig Rep (2015) 0.82
Immune reconstitution after combined haploidentical and umbilical cord blood transplant. Leuk Lymphoma (2013) 0.82
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma (2009) 0.82
Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma (2013) 0.81
Therapy-related acute myeloid leukemia/myelodysplasia with balanced 21q22 translocations. Am J Clin Pathol (2002) 0.81
Polymorphisms in the MLL breakpoint cluster region (BCR). Hum Genet (2003) 0.80
Analysis of translocations that involve the NUP98 gene in patients with 11p15 chromosomal rearrangements. Genes Chromosomes Cancer (2004) 0.79
Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy (2012) 0.79
An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol (2011) 0.79
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma (2008) 0.78
Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies. Expert Opin Pharmacother (2010) 0.78
Targeting mutations predictably. Blood (2011) 0.77
Chronic myeloid leukemia: current perspectives. Clin Lab Med (2011) 0.77
Comparative gene mapping in cattle, Indian muntjac, and Chinese muntjac by fluorescence in situ hybridization. Genetica (2008) 0.77
Generation of longer cDNA fragments from SAGE tags for gene identification. Methods Mol Biol (2003) 0.77
Harmful moratorium on stem cell research. Science (2002) 0.77
Two isoforms of HOXA9 function differently but work synergistically in human MLL-rearranged leukemia. Blood Cells Mol Dis (2012) 0.77
Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia. Expert Opin Pharmacother (2012) 0.76
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma (2010) 0.76
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma (2012) 0.76
Cytogenetic and molecular study of the PRDX4 gene in a t(X;18)(p22;q23): a cautionary tale. Cancer Genet Cytogenet (2007) 0.75
Myelofibrosis with myeloid metaplasia: where is the biology leading us? Semin Oncol (2005) 0.75
Screening poly [dA/dT(-)] cDNA for gene identification. Methods Mol Biol (2003) 0.75
Molecular cytogenetic characterization of breakpoints in 19 patients with hematologic malignancies and 12p unbalanced translocations. Cancer Genet Cytogenet (2003) 0.75
Prognostic significance of the AML1-ETO fusion transcript expression in children and young adults with t(8;21) acute myeloid leukemia. Haematologica (2003) 0.75
t(1;3)(p36;p21) is a recurring therapy-related translocation. Genes Chromosomes Cancer (2002) 0.75